Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain


Por: Suarez-Garcia, I, Ruiz-Alguero, M, Yubero, C, Moreno, C, Belza, M, Estebanez, M, de los Santos, I, Masia, M, Abad, G, Sanchez, J, Omar, M and Jarrin, I

Publicada: 1 feb 2020
Resumen:
Objectives To assess the attitudes and opinions about generic antiretroviral drugs (ARVs) and single-tablet regimen (STR) de-simplification among physicians prescribing HIV treatment in the cohort of the Spanish HIV/AIDS Research Network (CoRIS). Methods An online questionnaire with 27 structured questions was sent to all physicians (n=199) who prescribed ARVs among the 45 centres participating in the cohort. Results A total of 169 (84.9%) physicians answered the questionnaire. Only 4.1% of the physicians would never prescribe generic ARVs, but 53.3% would not prescribe them if the number of pills per day increased and 89.3% would not prescribe them if the number of doses per day increased. However, 84.0% of the physicians agreed to prescribe generic ARVs if doing so would decrease costs for the public healthcare system. The percentages of physicians stating that generic ARVs (compared with branded ones) would be associated with worse adherence, more adverse effects or more probability of virological failure, provided that the number of pills and doses per day would not change, were low: 0.6%, 7.7% and 3.6%, respectively. However, these percentages were much higher if the generic ARV entailed breaking an STR: 63.9%, 18.9% and 42.0%, respectively. Most physicians stated that they needed more information about the effectiveness and safety of generic ARVs and the price difference compared with their branded equivalents. Conclusions Although most physicians were confident about prescribing generic ARVs, the majority had strong concerns about de-simplifying STR, and they also needed more information about generic drugs.

Filiaciones:
Suarez-Garcia, I:
 Hosp Univ Infanta Sofia, Dept Internal Med, Infect Dis Grp, Madrid, Spain

 Univ Europea, Fac Ciencias Biomed, Madrid, Spain

Ruiz-Alguero, M:
 Inst Salud Carlos III, Natl Epidemiol Ctr, Madrid, Spain

Yubero, C:
 Hosp Univ Infanta Sofia, Dept Hosp Pharm, Madrid, Spain

Moreno, C:
 Inst Salud Carlos III, Natl Epidemiol Ctr, Madrid, Spain

Belza, M:
 Inst Salud Carlos III, Natl Sch Hlth, Madrid, Spain

 Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Madrid, Spain

Estebanez, M:
 Hosp Univ Gomez Ulla, Dept Internal Med, Infect Dis Unit, Madrid, Spain

 Univ Alcala de Henares, Fac Med, Madrid, Spain

de los Santos, I:
 Hosp Univ La Princesa, Dept Internal Med, Madrid, Spain

:
 Hosp Gen Univ Elche, Infect Dis Unit, Alicante, Spain

Abad, G:
 Hosp Univ Miguel Servet, Zaragoza, Spain

Sanchez, J:
 Hosp Univ Basurto, Dept Infect Dis, Bizkaia, Spain

Omar, M:
 Complejo Hosp Jaen, Infect Dis Unit, Jaen, Spain

Jarrin, I:
 Inst Salud Carlos III, Natl Epidemiol Ctr, Madrid, Spain
ISSN: 03057453





JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Editorial
OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 75 Número: 2
Páginas: 466-472
WOS Id: 000515116900027
ID de PubMed: 31665404
imagen Open Access

FULL TEXT

imagen Published Version CC BY 4.0

MÉTRICAS